LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.07 2.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2

Max

2.08

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-154K

Pardavimai

-32M

19M

P/E

Sektoriaus vid.

4

35.724

Pelno marža

-0.825

Darbuotojai

119

EBITDA

-24M

-939K

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+152.71% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-47M

330M

Ankstesnė atidarymo kaina

-0.41

Ankstesnė uždarymo kaina

2.07

Naujienos nuotaikos

By Acuity

56%

44%

323 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-27 22:51; UTC

Uždarbis

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Rev $4.01B

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Adj EPS $1.84

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H EPS $1.82

2025-08-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025-08-27 23:39; UTC

Uždarbis

Correction to Nvidia Earnings Article -- WSJ

2025-08-27 22:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-27 22:59; UTC

Rinkos pokalbiai

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025-08-27 22:58; UTC

Uždarbis

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025-08-27 22:57; UTC

Uždarbis

South32 FY Free Cash Flow $192 Million

2025-08-27 22:56; UTC

Uždarbis

South32 FY Total Capital Expenditure $1.35 Billion

2025-08-27 22:56; UTC

Uždarbis

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025-08-27 22:55; UTC

Uždarbis

South32 Net Cash $123 Million at June 30

2025-08-27 22:54; UTC

Uždarbis

South32: Focused on Maintaining Strong Operating Momentum

2025-08-27 22:53; UTC

Uždarbis

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025-08-27 22:53; UTC

Uždarbis

South32 Extends Capital Management Program for 12 Months

2025-08-27 22:52; UTC

Uždarbis

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025-08-27 22:50; UTC

Uždarbis

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025-08-27 22:50; UTC

Uždarbis

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025-08-27 22:45; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025-08-27 22:43; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025-08-27 22:43; UTC

Uždarbis

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources Net Debt $123 Million at June 30

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources FY Underlying Ebitda $527.7 Million

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

152.71% į viršų

12 mėnesių prognozė

Vidutinis 5.13 USD  152.71%

Aukščiausias 7 USD

Žemiausias 3.5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

323 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.